

# Obstetrics and Gynecology Practice Analysis Detailed Report

ARDMS approved March 2021.

CONFIDENTIALITY NOTICE

The information contained within this report is confidential and is for the exclusive use for Inteleos. No redistribution or subsequent disclosure of this document is permitted without prior authorization from Inteleos.

### Contents

| ACKNOWLEDGEMENTS   |
|--|
| EXECUTIVE SUMMARY  |
| BACKGROUND OF STUDY  |
| METHODOLOGY  |
| Selection and Profile of Subject Matter Experts4               |
| Workshop Panel4  |
| Remote Panel   |
| Panelist Interviews and Workshop4                              |
| Confirmation of Task Inventory5                                |
| Field Survey   |
| Field Survey Development                                       |
| Field Survey Structure and Instructions to Survey Participants |
| Survey Administration Procedure and Response Rate              |
| RESULTS  |
| Data Analysis  |
| Task Inventory Analysis  |
| Demographic Analysis   |
| Discussion of Results7   |
| Appendix A: Practice Analysis Panelists                        |
| Appendix B: Workshop Agenda9                                   |
| Appendix C: Instructions for Remote Panel                      |
| Appendix D: Task Importance Score and Committee Decision       |
| Appendix E: Demographics of Survey Respondents                 |
| Appendix G: Content Outline                                    |

Revision Hisotry: 2021-03-17

Added ARDMS Council Approval

# ACKNOWLEDGEMENTS

Thank you to the subject matter expert volunteers who spent many hours developing the task inventory, evaluating the survey and responses, and reviewing the final content outline. Also, thank you to the 400 Registered Diagnostic Medical Sonographers (RDMSs) certified in Obstetrics and Gynecology (OB/GYN) around the world who took the time to participate in the practice analysis survey. This study was completed through the efforts of many individuals at Inteleos who worked together to construct the survey, administer the survey, and analyze the data.

# **EXECUTIVE SUMMARY**

The American Registry for Diagnostic Medical Sonography (ARDMS), part of the Inteleos family of certifications, is the globally recognized standard of excellence in sonography. The ARDMS is responsible for the preparation of valid and reliable certification examinations in the field of sonography. Conducting practice analyses at the national and international levels allows the ARDMS to evaluate the current practice expectations and performance requirements within the field. The OB/GYN practice analysis collected information on the requisite OB/GYN knowledge, skills, and abilities essential to sonography professionals. The practice analysis kicked-off with a workshop held in May of 2019. A pilot survey of the task inventory developed by the workshop panel was sent to a second panel of SMEs. The practice analysis survey was administered in January 2021. The analysis and discussion of results by the OB/GYN Assessment Committee led to the recommended content outline found in Appendix F. This report details the methodology, data collection, analysis, and the recommended updated test content outline for the OB/GYN examination based on the results of the practice analysis.

## **BACKGROUND OF STUDY**

The ARDMS recognizes that diagnostic medical sonography is a valuable tool in the healthcare industry. There are several healthcare professions that utilize sonography in practice to increase the efficacy of their patient care. Successful mastery and demonstration of the knowledge and skills required to hold ARDMS sonographer credentials will provide sonographers with an additional source of validation. This will support the veracity of the diagnostic medical sonography exams that these practitioners perform. The OB/GYN examination assesses the knowledge, skills, and abilities in the areas of the female reproductive system as well as the fetus in the first, second, and third trimesters of pregnancy as related to diagnostic ultrasound.

# **METHODOLOGY**

### Selection and Profile of Subject Matter Experts

### Workshop Panel

A panel of 12 subject matter experts (SMEs) attended an in-person workshop. The panel members were volunteers, and some were members of the OB/GYN Assessment Committee (see Appendix A). The panel was chosen to be representative of the practice to the extent possible (demographic information can be found in Appendix A). 11 panelists held the RDMS certification in OB/GYN and one panelist was a practicing OB/GYN physician. A description of the workshop is below.

### **Remote Panel**

A second panel comprised of three subject matter experts who hold the RDMS OB/GYN certification reviewed the drafted task inventory from the workshop and were given an opportunity to provide clarification and feedback on the tasks via an online survey. Appendix A contains information regarding this panel. More details regarding the work of the remote panel are given below.

### **Panelist Interviews and Workshop**

Structured interviews were scheduled with panel members as schedules allowed to provide the facilitator background information about the practice. Workshop panel members attended the in-person workshop May 30-31, 2019. See Appendix B for the workshop agenda. The facilitator briefed the panel on the purpose and methods of practice analyses. Panel members were led through activities to determine broad categories of work and tasks that comprise the practice of an OB/GYN Sonographer. Using the results of these activities and discussions, the panel then developed a preliminary task inventory.

### **Confirmation of Task Inventory**

A remote panel was assembled to review the task inventory that was developed as part of the workshop. The remote panel was instructed to review all the tasks on the task inventory and provide feedback to improve clarity and clinical accuracy. The remote panel was also given an opportunity to add additional tasks to the task inventory that the workshop panel may have omitted. The instructions to the remote panel can be found in Appendix C. There was strong agreement between the remote panel and the workshop panel. The remote panel only identified one task that should be clarified. One panelist was unfamiliar with four of the tasks. This feedback was included in the development of the field survey as described in the next section.

### Field Survey

### Field Survey Development

Working with members of the OB/GYN Assessment Committee, Inteleos staff combined results from the remote panel and the initial task inventory from the workshop. The inventory was compared with the existing content outline to verify that no topics were inadvertently omitted and was edited as appropriate. The final task inventory was reviewed by the OB/GYN Assessment Committee and used to build the practice analysis survey.

### Field Survey Structure and Instructions to Survey Participants

The field survey was divided into two parts: demographic items and the task inventory items. A screening item was used at the beginning of the survey to ensure only those actively practicing OB/GYN sonography responded to the survey: "*Do you currently perform and/or teach OB/GYN ultrasound examinations*?" Participants who selected "No" were thanked for their time and their survey ended.

For the task inventory portion of the field survey, participants were asked to rate each task on scales of importance. The instructions for this section were:

In the next section of the survey, you will be examining tasks associated with being an **OB/GYN** Sonographer, and consider the following question:

How important is this task to the practice of OB/GYN Sonography...

- Absolutely essential
- Very important
- Of average importance
- Of little importance
- Not important at all

The rating scale and weighting calculations are described in the Data Analysis section below.

### Survey Administration Procedure and Response Rate

The survey was initially sent to a random sample of 3,000 RDMS registrants who are certified in OB/GYN. The survey was open from January 15-29, 2021. The survey was available to participants as a web-based survey through the survey platform Qualtrics®. All responses to the survey were kept confidential. 400 individuals completed the task inventory portion of the survey. Responses from participants who did not complete the task inventory were not used as part of the data analysis.

# OB/GYN Practice Analysis Report **RESULTS**

### **Data Analysis**

### Task Inventory Analysis

Each option for the 113 task inventory items was assigned the following importance score:

- Absolutely essential = 5
- Very important = 4
- Of average importance = 3
- Of little importance = 2
- Not important at all = 1

The mean importance score was calculated for each task (see Appendix D). Tasks were assigned to three categories to assist in the discussion of importance scores. The following instructions were provided to the committee:

- **Green:** Any task with an importance score of four or above. The committee was instructed that these tasks should only be removed from the outline if they are redundant or for some other extraordinary circumstance. A rationale must be provided if the task is recommended for removal.
- Yellow: Tasks with an importance score of less than four and greater than or equal to three. These tasks may be kept or removed. A rationale is required for any tasks that are removed.
- **Red:** Any task with an importance score lower than three. These tasks should be considered for removal. A rationale is required for any of these tasks that are kept.

Most of the OB/GYN tasks fell into the "green" category. Ten tasks fell into the "yellow" category and there were no "red" category tasks.

### Initial Domain Weightings

The mean importance scores for each task were summed within each domain. The sum of the mean importance score for each domain was divided by the total mean importance score to determine the initial domain weightings (Table 1).

| Domain                      | # Tasks | Importance Sum | Initial Domain Weightings |
|-----------------------------|---------|----------------|---------------------------|
| GYN Anatomy and Physiology  | 22      | 98.53          | 19%                       |
| OB First Trimester          | 13      | 60.13          | 12%                       |
| OB 2nd and 3rd Trimester    | 39      | 181.33         | 36%                       |
| Protocols                   | 23      | 102.37         | 20%                       |
| Physics and Instrumentation | 11      | 44.69          | 9%                        |
| Treatment                   | 5       | 20.54          | 4%                        |
| Total                       | 113     | 508            | 100%                      |

### Table 1. Initial Domain Weightings (Prior to Committee Call)

### Demographic Analysis

Responses to demographic questions were also analyzed. Appendix E contains highlights from the demographic analysis. The analysis shows the survey respondents are representative across the dimensions of gender identification, age, location, and primary job function. The demographic analysis also provided information regarding years of experience, volume of exams performed, and the degree to which the participants' work is devoted to Obstetrics and to Gynecology.

# OB/GYN Practice Analysis Report **Discussion of Results**

A conference call was held on February 17, 2021 with six members of the OB/GYN Assessment Committee and members of Inteleos staff. Prior to the call, the results of the data analysis and initial content outline weightings were shared with the assessment committee. During the call, the attendees reviewed the tasks and mean importance score, focusing on the 11 tasks with importance scores less than four. The committee recommended removing five tasks. Four of these tasks were in the yellow category. One task the committee recommended removing was a green task, however the committee felt like it was very similar to another task on the outline and would be redundant to keep it. The committee suggested some minor changes to the wording of tasks. All edits, comments, rationales, and decisions from the committee can be found in Appendix D.

The *Treatment* Domain had a low domain weighting and only five tasks. The committee recommended moving the five tasks from this domain to the *Protocols* Domain under the subdomain of *Sonographer Role in Procedures*. They also recommended changing the name of the domain to *Protocols and Procedures* to accommodate this change. The associated importance weightings were added to this domain. The committee reviewed and approved the new domain weightings (Table 2) which reflect the changes outlined above. After the call new names for the domains were suggested and approved by the committee. Original domain names are in parenthesis for reference.

| Domain (Original Domain Name)  | # Tasks | Importance Sum | % of Total |
|--|---------|----------------|------------|
| GYN Anatomy and Physiology<br>(Gynecology - Pelvic Anatomy and Physiology) | 20      | 90.46          | 19%        |
| Obstetrics - First Trimester<br>(OB First Trimester)                       | 13      | 60.13          | 12%        |
| Obstetrics Second/Third Trimester<br>(OB 2nd and 3rd Trimester)            | 39      | 181.33         | 37%        |
| Protocols and Procedures   | 26      | 115.62         | 24%        |
| Physics and Instrumentation  | 10      | 41.16          | 8%         |

Table 2. Final Committee Recommended Domain Weightings and New Domain Names

# FINAL CONTENT OUTLINE

The revised formatted content outline including domain weightings was provided to the OB/GYN Assessment Committee for final review and approval. This report, including the final version of the content outline recommended by the Assessment Committee will go to the ARDMS Council for approval. Upon approval of the content outline, this report will be amended to include the approval date. The final recommended content outline can be found in Appendix F.

### **Council Approval**

(Added 3/17/2021) Content outline was approved and will be used for the 2021 form building process (ARDMS Council Resolution 21401).

# **Appendix A: Practice Analysis Panelists**

#### Table 3. Workshop Panel

| First Name    | Last Name  | Certifications                  |
|---------------|------------|---------------------------------|
| Michael       | Bork       | MD                              |
| Tania         | Campbell   | RDMS (OBGYN, AB, BR); RVT       |
| Касу          | Jasper     | RDMS (OBGYN, AB)                |
| Kelly         | Jordan     | RDMS (OBGYN, AB), RVT           |
| Trisha        | Lennox     | RDMS (OBGYN, AB, BR)            |
| Lisa          | Linhart    | RDMS (OBGYN, AB, BR, VT); RVT   |
| Amanda        | McCullough | RDMS (OBGYN, AB); RDCS          |
| Stephen       | McGlade    | RDMS (OBGYN, AB, Fem)           |
| Helen         | Michaels   | RDMS (OBGYN,AB, BR); RDCS       |
| Cara          | Vickery    | RDMS (OBGYN, BR)                |
| Winslow (Ted) | Whitten    | RDMS (OBGYN, AB, PS); RVT       |
| Janette       | Wybo       | RDMS (OBGYN, AB, BR); RDCS; RVT |

#### Table 4. Remote Panel

| First Name | Last Name   | Certifications       |
|------------|-------------|----------------------|
| Sarah      | Miller      | RDMS (OBGYN, AB, BR) |
| Alexis     | Christopher | RDMS (OBGYN)         |
| Amy        | Hatchner    | RDMS (OBGYN, AB)     |

### Table 5. Gender Identification of Population and Panelists

| Gender | Percent in Population | Panelists | Percent of Panelists |
|--------|-----------------------|-----------|----------------------|
| Female | 92 %                  | 12        | 80%                  |
| Male   | 8 %                   | 3         | 20 %                 |

### Table 6. U.S. Region or Country of Population and Panels

| Region/Country | Percent in Population | Panelists | Percent of Panelists |
|----------------|-----------------------|-----------|----------------------|
| Midwest        | 21%                   | 5         | 33.3 %               |
| Northeast      | 17%                   | 1         | 6.7 %                |
| South          | 33%                   | 4         | 26.7 %               |
| West           | 20%                   | 4         | 26.7 %               |
| Canada         | 8%                    | 1         | 6.7 %                |
| Other          | 1%                    | 0         | 0%                   |

# Appendix B: Workshop Agenda

### Practice Analysis Workshop for OBGYN Exam May 30-31, 2019

#### Meeting Location: Inteleos, 1401 Rockville Pike, Suite 600, Rockville, MD 20852

| Thursday, May 30   |   |                       |
|--------------------|---|-----------------------|
| 8:00 - 8:30 AM     | Breakfast   |                       |
| 8:30 - 9:00 AM     | <ul><li>Welcome and Housekeeping:</li><li>Wi-Fi Access</li><li>Introductions</li></ul>                          | Hannah Gibson & Panel |
| 9:00 - 9:30 AM     | Overview and Purpose of Workshop  | Joe Costa             |
| 9:30 - 10:00 AM    | Review Preliminary Report   | Joe Costa             |
|                    | <ul> <li>How the data will be used</li> <li>Feedback</li> <li>Item Bank Health</li> <li>Gap Analysis</li> </ul> |                       |
| 10:00 AM - 2:00 PM | Review & Revise the Prepared Task<br>Inventory  | Joe Costa & Panel     |
| 12:00 - 1:00 PM    | Lunch   |                       |
| 1:00 - 2:00 PM     | Review Task Inventory in Qualtrics  | Panel                 |
| 2:00 - 4:30 PM     | Finalize Task Inventory   | Joe Costa & Panel     |
| Friday, May 31     |   |                       |
| 8:00 - 8:30 AM     | Breakfast   |                       |
| 8:30 - 12:00 PM    | Knowledge-to-Task Linkage Exercise  | Joe Costa & Panel     |
| 12:00 - 1:00 PM    | Lunch   |                       |
| 1:00 PM - 4:30 PM  | Item Development Workshop   | Hannah Gibson         |

#### Panel Members

- Michael Bork
- Tania Campbell

Kacy Jasper

- Kelly Jordan
- Lisa Linhart
- Trisha Lennox
- Amanda McCullough
- Stephen McGlade
- Helen Michaels
- Cara Vickery
- Ted Whitten
- Janette Wybo

#### Inteleos Staff

- Joe Costa, Research Scientist
- Hannah Gibson, Senior Exam
   Program Manager

### **Appendix C: Instructions for Remote Panel**

#### Instructions Regarding Clarity of Statements:

You are about to review 31 statements that reflect job responsibilities of a diagnostic medical sonographer certified in OB/GYN. Each statement will be presented one at a time.

After you have read the statement, use your expert judgement to choose the most appropriate option. Each statement will be preceded with this phrase: "Would you expect a diagnostic medical sonographer certified in OBGYN to." The framework below is an example.

# Would you expect a diagnostic medical sonographer certified in OB/GYN to: **[STATEMENT WILL APPEAR HERE].**

You will have the following options:

Yes, this statement is accurate and clear. No, this statement is inaccurate or unclear. I believe this task is not performed by a diagnostic medical sonographer who is certified in OBGYN. I am unfamiliar with this task.

#### Guidelines on how to select the appropriate option

You should choose **option 1** if the statement is an accurate reflection of a job responsibility for a sonographer certified in OB/GYN. You should also choose option 1 if after reading the statement, the meaning of the statement is clear and you would reasonably expect any sonographer certified in OB/GYN to interpret this statement correctly.

You should choose **option 2** if the statement is inaccurate. For example, in your expert opinion, you might believe that rewording the statement will make it more accurate. You should also choose option 2 if the statement is unclear. If you choose this statement, you believe that a sonographer certified in OB/GYN will have difficulty interpreting the meaning of this statement. Note, if you select option 2, you will be given the opportunity to make the statement more accurate or more clear.

You should choose **option 3** if you believe the statement is *outside* the scope of practice for a sonographer certified in OB/GYN. For example, you can choose this statement if another employee (e.g., physician) would perform this statement but not a sonographer.

You should choose **option 4** if you are unfamiliar with the task or uncomfortable making a judgment of the task.

#### Instructions Regarding Missing or Redundant Information:

First, please review the entire task list in the image below. Then, below the image, select the box next to the statements that you believe are <u>true.</u>

There are tasks, performed by a diagnostic medical sonographer who is certified in OB/GYN missing from the picture above. (1)

There are duplicate or redundant tasks in the picture above. (2)

#### If either option was selected, an open-ended text box was provided with the following prompt:

You indicated that there are missing tasks or redundant information. Please provide more detail in the box below. Which tasks would you add? Or what redundant information would you remove?

## Appendix D: Task Importance Score and Committee Decision

Tasks in the "Green" category have a mean importance score of four or greater. Tasks in the "Yellow" category have a mean importance score of greater than or equal to three and less than four. Tasks in the "Red" category have a mean importance score of less than three. In general, all "green" tasks are kept, and "red" tasks are removed. The committee's decisions are recorded above (column D shows if they decided to keep it and column E shows any edits to the task and rationales for removing tasks.

| A.<br>Tasks | B. Domain & Task  | C.<br>Importance<br>Value | D.<br>Keep? | E. Cmte.<br>Comment or<br>Rationale |
|-------------|---|---------------------------|-------------|-------------------------------------|
| Tasks       | Gynecology - Pelvic Anatomy and Physiology                      | Value                     | incep.      | hationale                           |
|             | Normal Anatomy and Physiology                                   |                           |             |                                     |
|             | Assess the uterus (i.e., size, position, orientation,           |                           |             |                                     |
| 1           | contour, echogenicity)  | 4.83                      | Yes         |                                     |
| 2           | Assess the myometrium   | 4.64                      | Yes         |                                     |
| 3           | Assess the endometrium (i.e., cyclic changes)                   | 4.69                      | Yes         |                                     |
| 4           | Assess the vagina and cervix                                    | 4.30                      | Yes         |                                     |
|             | Assess both adnexa (i.e., ovaries, fallopian tubes,             |                           |             |                                     |
| 5           | pelvic musculature)   | 4.81                      | Yes         |                                     |
| 6           | Assess the anterior and posterior cul-de-sacs                   | 4.32                      | Yes         |                                     |
|             | Assess premenarcheal, reproductive, and                         |                           |             |                                     |
| 7           | postmenopausal patients   | 4.44                      | Yes         |                                     |
|             | Abnormal Physiology and Perfusion                               |                           |             |                                     |
|             | Evaluate for Müllerian duct developmental                       |                           |             |                                     |
|             | anomalies (e.g., septated, subseptate, arcuate,                 |                           |             |                                     |
| 8           | bicornuate, unicornis uterus)                                   | 4.22                      | Yes         |                                     |
|             | Evaluate for abnormal fluid collections (e.g.,                  |                           |             | Added free                          |
| 0           | hydrometra, pyometra, hydrometrocolpos,                         | 4.50                      | Maa         | fluid as an                         |
| 9           | hematometrocolpos, free fluid)                                  | 4.56                      | Yes         | example                             |
| 10          | Evaluate for uterine leiomyomas (e.g., intramural,              | 4.50                      |             |                                     |
| 10          | submucosal, subserosal, pedunculated)                           | 4.53                      | Yes         |                                     |
| 11          | Evaluate for adenomyosis and endometriosis (e.g., endometrioma) | 4.42                      | Yes         |                                     |
| 11          | Evaluate for endometrial pathology (e.g.,                       | 4.42                      | 165         |                                     |
|             | endometrial fluid, polyps, endometrial hyperplasia,             |                           |             |                                     |
| 12          | endometrial carcinoma)  | 4.77                      | Yes         |                                     |
|             | Evaluate for cervical pathology (e.g., polyps,                  |                           |             |                                     |
|             | nabothian cysts, cervical stenosis, cervical                    |                           |             |                                     |
| 13          | carcinoma)  | 4.38                      | Yes         |                                     |
|             | Evaluate for vaginal pathology (e.g., Gartner cyst,             |                           |             | Covered in                          |
| 14          | imperforate hymen, hematometra)                                 | 3.81                      | No          | Task 9                              |

| 15       section scar, leiomyosarcoma)       4.17       Yes         Evaluate for functional ovarian cysts (e.g., follicular, corpus luteum, theca-lutein)       4.20       Yes         Evaluate for benign ovarian neoplasms (e.g., paraovarian, cystadenoma (serous, mucinous, papillary), cystic teratoma, fibroma, thecoma, and the papillary (systadenotarcinoma, metastatic, serous carcinoma, mucinous cystadenocarcinoma, papillary cystadenocarcinoma, metastatic, and the ovarian hyperstimulation syndrome, polycystic       Yes         18       Krukenberg)       4.80       Yes         19       ovarian disease)       4.78       Yes         20       Evaluate for free fluid in the pelvis       4.27       No       Covered in Task 9         3       Assess for intrauterine contraceptive device (IUCD)       4.54       Yes       Yes         21       Evaluate for free fluid in the pelvis       4.57       Yes       Covered in Task 9         3       Assess for intrauterine contraceptive device (IUCD)       4.54       Yes       Yes         22       location       4.54       Yes       Secondard Anatomy and Physiology First Trimester       Secondard Anatomy and Physiolog   | 1  | Evaluate other uterine findings (e.g., caesarean-        |       |     |            |
|---|----|--|-------|-----|------------|
| 16       corpus luteum, theca-lutein)       4.20       Yes         Evaluate for benign ovarian neoplasms (e.g., paraovarian, cystadenoma [serous, mucinous, papillary], cystic teratoma, fibroma, thecoma, arrhenoblastoma)       4.57       Yes         Evaluate for malignant ovarian neoplasms (e.g., serous carcinoma, mucinous cystadenocarcinoma, papillary cystadenocarcinoma, metastatic, arrhenoblastoma)       4.57       Yes         Evaluate other ovarian findings (e.g., ovarian torsion, ovarian hyperstimulation syndrome, polycystic       4.78       Yes         19       ovarian hyperstimulation syndrome, polycystic       70       Task 9         20       Evaluate for free fluid in the pelvis       4.78       Yes         21       endometritis, pyosalpinx, tubo-ovarian abscess)       4.50       Yes         22       location       4.54       Yes         23       gestational sac, yolk sac, emproy, aminon)       4.82       Yes         24       Identify structures in the first trimester obstetrical exam less than 10 weeks (i.e., decidual reaction, egstational isac, yolk sac, emproy, aminon)       4.82       Yes         24       insertion, limbs)       4.32       Yes       14         25       chority freal anatomy in the first trimester obstetrical examination between 10-14 weeks' gestational isac, yolk sac, emproy, aminon)       4.82       Yes         25       chority freal ana  | 15 |  | 4.17  | Yes |            |
| 16       corpus luteum, theca-lutein)       4.20       Yes         Evaluate for benign ovarian neoplasms (e.g., paraovarian, cystadenoma [serous, mucinous, papillary], cystic teratoma, fibroma, thecoma, arrhenoblastoma)       4.57       Yes         Evaluate for malignant ovarian neoplasms (e.g., serous carcinoma, mucinous cystadenocarcinoma, papillary cystadenocarcinoma, metastatic, arrhenoblastoma)       4.57       Yes         Evaluate other ovarian findings (e.g., ovarian torsion, ovarian hyperstimulation syndrome, polycystic       4.78       Yes         19       ovarian hyperstimulation syndrome, polycystic       70       Task 9         20       Evaluate for free fluid in the pelvis       4.27       No       Task 9         21       endometritis, pyosalpinx, tubo-ovarian abscess)       4.50       Yes       Ves         21       edometritis, pyosalpinx, tubo-ovarian abscess)       4.50       Yes       Ves         22       location       4.54       Yes       Ves   |    | Evaluate for functional ovarian cysts (e.g., follicular, |       |     |            |
| Evaluate for benign ovarian neoplasms (e.g., paraovarian, cystadenoma [serous, mucinous, papillary], cystic teratoma, fibroma, thecoma, arrhenoblastoma)       4.57       Yes         Evaluate for malignant ovarian neoplasms (e.g., serous carcinoma, mucinous cystadenocarcinoma, papillary cystadenocarcinoma, metastatic, Krukenberg)       4.80       Yes         Evaluate for malignant ovarian neoplasms (e.g., serous carcinoma, mucinous cystadenocarcinoma, ovarian hyperstimulation syndrome, polycystic ovarian torsion, ovarian tisease)       4.80       Yes         Evaluate other ovarian findings (e.g., ovarian torsion, ovarian disease)       4.78       Yes         20       Evaluate for free fluid in the pelvis       4.27       No       Task 9         Assess for pelvic inflammatory disease (e.g., endometritis, pyosalpinx, tubo-ovarian abscess)       4.50       Yes       Covered in         21       location       4.54       Yes       Yes       Covered in         22       location       4.54       Yes       Yes       Covered in         23       gestational Anatomy and Physiology First Trimester       Mormal Anatomy and Physiology First Trimester       Ves       Yes         24       insertical examination between 10-14 weeks' gestation (i.e., calvarium, brain, stomach, cord       Yes       Yes       Yes         25       chorionicity/ammionicity)       4.82       Yes       Yes       Yes   | 16 |  | 4.20  | Yes |            |
| papillary], cystic teratoma, fibroma, thecoma,<br>arrhenoblastoma)4.57YesEvaluate for malignant ovarian neoplasms (e.g.,<br>serous carcinoma, mucinous cystadenocarcinoma,<br>papillary cystadenocarcinoma, metastatic,<br>(avarian hyperstimulation syndrome, polycystic<br>ovarian hyperstimulation syndrome, polycystic<br>ovarian hyperstimulation syndrome, polycystic<br>ovarian hyperstimulation syndrome, polycystic<br>4.80Yes20Evaluate other ovarian findings (e.g., ovarian torsion,<br>ovarian hyperstimulation syndrome, polycystic<br>ovarian hyperstimulation syndrome, polycysticCovered in<br>Task 920Evaluate for free fluid in the pelvis4.27NoTask 921endometritis, pyosalpinx, tubo-ovarian abscess)4.50Yes22location4.54Yes23location4.54Yes24lobstetrics - First TrimesterImage: construction operation operat  |    | Evaluate for benign ovarian neoplasms (e.g.,             |       |     |            |
| 17arrhenoblastoma)4.57YesEvaluate for malignant ovarian neoplasms (e.g.,<br>serous carcinoma, mucinous cystadenocarcinoma,<br>papillary cystadenocarcinoma, metastatic,<br>towarian hyperstimulation syndrome, polycystic   |    | paraovarian, cystadenoma [serous, mucinous,              |       |     |            |
| Evaluate for malignant ovarian neoplasms (e.g., serous carcinoma, mucinous cystadenocarcinoma, papillary cystadenocarcinoma, metastatic, Krukenberg)       4.80       Yes         18       Krukenberg)       4.80       Yes         Evaluate other ovarian findings (e.g., ovarian torsion, ovarian hyperstimulation syndrome, polycystic       4.78       Yes         19       ovarian disease)       4.78       Yes         20       Evaluate for free fluid in the pelvis       4.27       No       Task 9         Assess for pelvic inflammatory disease (e.g., endometritis, pyosalpinx, tubo-ovarian abscess)       4.50       Yes         21       endometritis, pyosalpinx, tubo-ovarian abscess)       4.50       Yes         22       location       4.54       Yes         23       gestational sac, yolk sac, embryo, amnion)       4.82       Yes         24       insertion, limbs)       4.82       Yes         25       chorionicity/amnionicity)       4.84       Yes         24       insertion, limbs)       4.32       Yes         25       chorionicity/amnionicity)       4.84       Yes         26       Evaluate for ectopic and heterotopic pregnancy       4.22       Yes         25       chorionicity/amnionicity)       4.84       Yes         26  |    | papillary], cystic teratoma, fibroma, thecoma,           |       |     |            |
| serous carcinoma, mucinous cystadenocarcinoma,<br>papillary cystadenocarcinoma, metastatic,<br>Krukenberg)4.80Yes18Krukenberg)4.80YesEvaluate other ovarian findings (e.g., ovarian torsion,<br>ovarian hyperstimulation syndrome, polycystic4.78Yes20Evaluate for free fluid in the pelvis4.78Yes21endometritis, pyosalpinx, tubo-ovarian abscess)4.50Yes21endometritis, pyosalpinx, tubo-ovarian abscess)4.50Yes22location4.54Yes23costorin4.54Yes24hyperstinuterine contraceptive device (IUCD)<br>coation4.54Yes25lobatetrics - First Trimester4.50Yes26Normal Anatomy and Physiology First Trimester4.50Yes27lobatetrica examination between 10-14 weeks'<br>gestation (i.e., calvarium, brain, stomach, cord4.32Yes26Evaluate for gestations (i.e., fetal number,<br>chorionicity/amnionicity)4.32Yes27Evaluate for ectopic and heterotopic pregnancy4.92Yes28Evaluate for ectopic and heterotopic pregnancy4.92Yes29Evaluate for increased nuchal translucency4.43Yes20Evaluate for intrauterine contraceptive device (IUCD)<br>assesYes39gestation (i.e., fetal number,<br>chorinicity/amnionicity)Yes40First Trimester Abnormalities and Complications41fentify multiple gestational trophoblastic disease   | 17 | arrhenoblastoma)   | 4.57  | Yes |            |
| papillary cystadenocarcinoma, metastatic,<br>Krukenberg)4.80YesEvaluate other ovarian findings (e.g., ovarian torsion,<br>ovarian hyperstimulation syndrome, polycystic4.80Yes19ovarian hyperstimulation syndrome, polycystic4.78Yes20Evaluate for free fluid in the pelvis4.78Yes21endometritis, pyosalpinx, tubo-ovarian abscess)4.50Yes22location4.54Yes23gestational society of the first trimester4.54Yes24Normal Anatomy and Physiology First Trimester4.54Yes25obstetrics - First Trimester4.54Yes26Udentify structures in the first trimester obstetrical<br>exam less than 10 weeks (i.e., decidual reaction,<br>gestational sac, yolk sac, embryo, amnion)4.82Yes26Identify fretal anatomy in the first trimester<br>obstetrical examination between 10-14 weeks'<br>gestation (i.e., calvarium, brain, stomach, cord4.32Yes25chorinonicity/amnionicity)4.84Yes1026Evaluate for gestational (tophoblastic disease4.62Yes27Evaluate for ectopic and heterotopic pregnancy4.92Yes28Evaluate for anembryonic/fetal demise4.84Yes29Evaluate for subtornic hemorrhage4.33Yes30Evaluate for increased nuchal translucency4.66Yes31Evaluate for intrauterine contraceptive device (IUCD)<br>33with pregnancy4.6033with pregnancy4.60Yes<   |    |  |       |     |            |
| 18Krukenberg)4.80YesEvaluate other ovarian findings (e.g., ovarian torsion,<br>ovarian hyperstimulation syndrome, polycystic4.78Yes19ovarian disease)4.78Yes20Evaluate for free fluid in the pelvis4.27NoTask 9Assess for pelvic inflammatory disease (e.g.,<br>endometritis, pyosalpinx, tubo-ovarian abscess)4.50Yes21endometritis, pyosalpinx, tubo-ovarian abscess)4.50Yes22location4.54Yes23location4.54Yes24normal Anatomy and Physiology First Trimester0 </td <td></td> <td></td> <td></td> <td></td> <td></td>   |    |  |       |     |            |
| Evaluate other ovarian findings (e.g., ovarian torsion,<br>ovarian hyperstimulation syndrome, polycystic<br>ovarian disease)4.78Yes20Evaluate for free fluid in the pelvis4.78Yes20Evaluate for free fluid in the pelvis4.27NoTask 921endometritis, pyosalpinx, tubo-ovarian abscess)4.50YesAssess for intrauterine contraceptive device (IUCD)22location4.54YesIonatomy and Physiology First TrimesterIonatomy and Physiology First Trimester23gestational sac, yolk sac, embryo, amnion)4.82YesIonatomy and Physiology First Trimester24insertion, limbs)4.32YesIonatomy and Physiology First Trimester25chorionicity/amnionicity)4.84YesYes26Evaluate for gestational trophoblastic disease4.62Yes26Evaluate for ecopic and heterotopic pregnancy4.32Yes26Evaluate for ecopic and heterotopic pregnancy4.75Yes27Evaluate for anembryonic/fetal demise4.84Yes28Evaluate for subchorionic typic pregnancy4.75Yes29Evaluate for increased nuchal translucency4.46Yes30Evaluate for intrauterine contraceptive device (IUCD)33with pregnancy33with pregnancy4.60Yes34Evaluate for incomplet/missed abortion, andEvaluate for incomplet/missed abortion, and  |    |  |       |     |            |
| ovarian hyperstimulation syndrome, polycystic<br>ovarian disease)4.78Yes19ovarian disease)4.78Yes20Evaluate for free fluid in the pelvis4.27NoTask 921assess for pelvic inflammatory disease (e.g.,<br>endometritis, pyosalpinx, tubo-ovarian abscess)4.50Yes22location4.54Yes23costerrice - First Trimester111Identify structures in the first trimester obstetrical<br>exam less than 10 weeks (i.e., decidual reaction,<br>gestational sac, yolk sac, embryo, amnion)4.82Yes24insertion, limbs)4.32Yes25chorionicity/amnionicity)4.84Yes26Evaluate for ecopic and heterotopic pregnancy4.23Yes26Evaluate for ecopic and heterotopic pregnancy4.32Yes27Evaluate for ecopic and heterotopic pregnancy4.32Yes28Evaluate for ecopic and heterotopic pregnancy4.22Yes29Evaluate for anomynoic/fetal demise4.84Yes29Evaluate for incraesed nuchal translucency4.34Yes30Evaluate for intrauterine contraceptive device (IUCD)4.33Yes33with pregnancy4.36Yes33with pregnancy4.60Yes <tr< td=""><td>18</td><td></td><td>4.80</td><td>Yes</td><td></td></tr<>  | 18 |  | 4.80  | Yes |            |
| 19ovarian disease)4.78Yes20Evaluate for free fluid in the pelvis4.27NoTask 921endometritis, pyosalpinx, tubo-ovarian abscess)4.50YesYes22iocation4.54YesYes23location4.54YesYes24Obstetrics - First Trimester2221Identify structures in the first trimester obstetrical<br>exam less than 10 weeks (i.e., decidual reaction,<br>gestational sac, yolk sac, embryo, amnion)4.82Yes25Identify fetal anatomy in the first trimester<br>obstetrical examination between 10-14 weeks'<br>gestation (i.e., calvarium, brain, stomach, cord<br>insertion, limbs)Yes226Evaluate for gestational trophoblastic disease4.62Yes227Evaluate for gestational trophoblastic disease4.62Yes228Evaluate for abnormal tregongrancy4.32Yes229Evaluate for increased nuchal translucency4.33Yes230Evaluate for increased nuchal translucency4.34Yes231Evaluate for increased nuchal translucency4.66Yes233with pregnancy4.60Yes2233with pregnancy4.60Yes3344For subchorionic hemorrhage4.33Yes3  |    |  |       |     |            |
| 20Evaluate for free fluid in the pelvis4.27NoCovered in<br>Task 921Assess for pelvic inflammatory disease (e.g.,<br>endometritis, pyosalpinx, tubo-ovarian abscess)4.50Yes22Identify structure contraceptive device (IUCD)<br>location4.54Yes22Identify structures in the first trimester4.54Yes23gestational sac, yolk sac, embryo, amnion)4.82Yes24identify fetal anatomy in the first trimester<br>obstetrical examination between 10-14 weeks'<br>gestation (i.e., calvarium, brain, stomach, cord4.32Yes24insertion, limbs)4.32Yes4.32Yes25Evaluate for gestational tophoblastic disease4.62Yes26Evaluate for gestational tophoblastic disease4.62Yes27Evaluate for anomnal yolk sac4.39Yes28Evaluate for anomnal yolk sac4.39Yes31Evaluate for increased nuchal translucency4.46Yes32Evaluate for intrauterine contraceptive device (IUCD)<br>33with pregnancy4.60Yes   | 10 |  | 1 70  | Voc |            |
| 20Evaluate for free fluid in the pelvis4.27NoTask 9Assess for pelvic inflammatory disease (e.g.,<br>endometritis, pyosalpinx, tubo-ovarian abscess)4.50Yes21endometritis, pyosalpinx, tubo-ovarian abscess)4.50Yes22location4.54Yes23location4.54Yes24Identify structures in the first trimester25gestational sac, yolk sac, embryo, amnion)4.82Yes26Identify fetal anatomy in the first trimester<br>obstetrical examination between 10-14 weeks'<br>gestation (i.e., calvarium, brain, stomach, cord26Evaluate for gestations (i.e., fetal number,<br>chorionicity/amnionicity)4.32Yes27Evaluate for gestational trophoblastic disease4.62Yes28Evaluate for embryonic/fetal demise4.84Yes29Evaluate for anembryonic pregnancy4.75Yes30Evaluate for increased nuchal translucency4.36Yes32Evaluate for intrauterine contraceptive device (IUCD)<br>at the regeneraceYes33with pregnancy4.33Yes   | 19 | ovarian disease)   | 4.76  | 165 | Covered in |
| Assess for pelvic inflammatory disease (e.g.,<br>endometritis, pyosalpinx, tubo-ovarian abscess)4.50Yes21endometritis, pyosalpinx, tubo-ovarian abscess)4.50YesAssess for intrauterine contraceptive device (IUCD)<br>location4.54Yes22location4.54YesObstetrics - First TrimesterIdentify structures in the first trimester obstetrical<br>exam less than 10 weeks (i.e., decidual reaction,<br>gestational sac, yolk sac, embryo, amnion)4.82YesIdentify fetal anatomy in the first trimester<br>obstetrical examination between 10-14 weeks'<br>gestation (i.e., calvarium, brain, stomach, cord4.32YesIdentify multiple gestations (i.e., fetal number,<br>First Trimester Abnormalities and Complications4.84Yes26Evaluate for gestational trophoblastic disease4.62Yes27Evaluate for entropionic/fetal demise4.84Yes28Evaluate for and heterotopic pregnancy4.75Yes30Evaluate for anonnal yolk sac4.39Yes31Evaluate for increased nuchal translucency4.46Yes32Evaluate for increased nuchal translucency4.46Yes33with pregnancy4.33Yes  | 20 | Evaluate for free fluid in the pelvis                    | 4 27  | No  |            |
| 21endometritis, pyosalpinx, tubo-ovarian abscess)4.50YesAssess for intrauterine contraceptive device (IUCD)4.54Yes22location4.54YesObstetrics - First TrimesterImage: Control of the trimester obstetricalImage: Control of trimester obstetrical1Identify structures in the first trimester obstetricalImage: Control of trimester obstetricalImage: Control of trimester obstetrical23gestational sac, yolk sac, embryo, amnion)4.82Yes1Identify fetal anatomy in the first trimester<br>obstetrical examination between 10-14 weeks'<br>gestation (i.e., calvarium, brain, stomach, cordImage: Control of trimester<br>obstetrical examination between 10-14 weeks'<br>gestation (i.e., calvarium, brain, stomach, cordImage: Control of trimester<br>obstetrical examination between 10-14 weeks'<br>gestation (i.e., calvarium, brain, stomach, cordImage: Control of trimester<br>obstetrical examination between 10-14 weeks'<br>gestation (i.e., calvarium, brain, stomach, cordImage: Control of trimester<br>obstetrical examination between 10-14 weeks'<br>gestation (i.e., calvarium, brain, stomach, cordImage: Control of trimester<br>obstetrical examination between 10-14 weeks'<br>gestation (i.e., calvarium, brain, stomach, cordImage: Control of trimester<br>obstetrical examination between 10-14 weeks'<br>gestation (i.e., calvarium, brain, stomach, cordImage: Control of trimester<br>trimester24insertion, limbs)4.32YesImage: Control of trimester<br>trimester25chorionicity/manionicity)4.84YesImage: Control of trimester26Evaluate for gestational trophoblastic disease <t< td=""><td>20</td><td></td><td>-1.27</td><td></td><td></td></t<>  | 20 |  | -1.27 |     |            |
| Assess for intrauterine contraceptive device (IUCD)<br>location4,54Yes22location4,54YesObstetrics - First TrimesterImage: Control of Co   | 21 |  | 4 50  | Voc |            |
| 22location4.54YesObstetrics - First TrimesterIINormal Anatomy and Physiology First TrimesterIIIdentify structures in the first trimester obstetrical<br>exam less than 10 weeks (i.e., decidual reaction,<br>gestational sac, yolk sac, embryo, amnion)4.82YesIdentify fetal anatomy in the first trimester<br>obstetrical examination between 10-14 weeks'<br>gestation (i.e., calvarium, brain, stomach, cordII24insertion, limbs)4.32YesIdentify multiple gestations (i.e., fetal number,<br>chorionicity/amnionicity)4.84YesFirst Trimester Abnormalities and ComplicationsI26Evaluate for gestational trophoblastic disease4.62Yes27Evaluate for ectopic and heterotopic pregnancy4.92Yes28Evaluate for anembryonic pregnancy4.75Yes30Evaluate for anormal yolk sac4.33Yes31Evaluate for increased nuchal translucency4.46Yes33with pregnancy4.60Yes33with pregnancy4.60Yes  | 21 |  | 4.50  | res |            |
| Obstetrics - First TrimesterImage: Construct of the second se | 22 |  | 4 54  | Ves |            |
| Normal Anatomy and Physiology First TrimesterImage: Construct of the second |    |  |       | 103 |            |
| Identify structures in the first trimester obstetrical<br>exam less than 10 weeks (i.e., decidual reaction,<br>gestational sac, yolk sac, embryo, amnion)4.82Yes23gestational sac, yolk sac, embryo, amnion)4.82YesIdentify fetal anatomy in the first trimester<br>obstetrical examination between 10-14 weeks'<br>gestation (i.e., calvarium, brain, stomach, cord4.32Yes24insertion, limbs)4.32YesIdentify multiple gestations (i.e., fetal number,<br>chorionicity/amnionicity)4.84YesFirst Trimester Abnormalities and Complications4.82Yes26Evaluate for gestational trophoblastic disease4.62Yes27Evaluate for ectopic and heterotopic pregnancy4.92Yes28Evaluate for embryonic/fetal demise4.84Yes29Evaluate for anembryonic pregnancy4.75Yes30Evaluate for abnormal yolk sac4.39Yes31Evaluate for subchorionic hemorrhage4.33Yes32Evaluate for subchorionic hemorrhage4.33Yes33with pregnancy4.60Yes33with pregnancy4.60Yes  |    |  |       |     |            |
| exam less than 10 weeks (i.e., decidual reaction,<br>gestational sac, yolk sac, embryo, amnion)4.82Yes23gestational sac, yolk sac, embryo, amnion)4.82Yes1Identify fetal anatomy in the first trimester<br>obstetrical examination between 10-14 weeks'<br>gestation (i.e., calvarium, brain, stomach, cord   |    |  |       |     |            |
| Identify fetal anatomy in the first trimester<br>obstetrical examination between 10-14 weeks'<br>gestation (i.e., calvarium, brain, stomach, cord24insertion, limbs)4.32Identify multiple gestations (i.e., fetal number,<br>chorionicity/amnionicity)4.84YesFirst Trimester Abnormalities and Complications  |    |  |       |     |            |
| obstetrical examination between 10-14 weeks'<br>gestation (i.e., calvarium, brain, stomach, cordI24insertion, limbs)4.32YesIdentify multiple gestations (i.e., fetal number,<br>chorionicity/amnionicity)4.84Yes <b>First Trimester Abnormalities and ComplicationsII</b> 26Evaluate for gestational trophoblastic disease4.62Yes27Evaluate for ectopic and heterotopic pregnancy4.92Yes28Evaluate for embryonic/fetal demise4.84Yes29Evaluate for anembryonic pregnancy4.75Yes30Evaluate for increased nuchal translucency4.46Yes31Evaluate for subchorionic hemorrhage4.33Yes32Evaluate for intrauterine contraceptive device (IUCD)<br>33YesI33with pregnancy4.60Yes   | 23 | gestational sac, yolk sac, embryo, amnion)               | 4.82  | Yes |            |
| gestation (i.e., calvarium, brain, stomach, cord<br>insertion, limbs)Yes24insertion, limbs)4.32YesIdentify multiple gestations (i.e., fetal number,<br>chorionicity/amnionicity)4.84Yes <b>First Trimester Abnormalities and ComplicationsI</b> 26Evaluate for gestational trophoblastic disease4.62Yes27Evaluate for ectopic and heterotopic pregnancy4.92Yes28Evaluate for embryonic/fetal demise4.84Yes29Evaluate for anembryonic pregnancy4.75Yes30Evaluate for abnormal yolk sac4.39Yes31Evaluate for subchorionic hemorrhage4.33Yes32Evaluate for intrauterine contraceptive device (IUCD)Yes33with pregnancy4.60Yes4Evaluate for incomplet/missed abortion, andII  |    | Identify fetal anatomy in the first trimester            |       |     |            |
| 24insertion, limbs)4.32YesIdentify multiple gestations (i.e., fetal number,<br>chorionicity/amnionicity)4.84Yes25chorionicity/amnionicity)4.84Yes <b>First Trimester Abnormalities and Complications</b>  |    | obstetrical examination between 10-14 weeks'             |       |     |            |
| Identify multiple gestations (i.e., fetal number,<br>chorionicity/amnionicity)4.84YesFirst Trimester Abnormalities and Complications4.84Yes26Evaluate for gestational trophoblastic disease4.62Yes27Evaluate for ectopic and heterotopic pregnancy4.92Yes28Evaluate for embryonic/fetal demise4.84Yes29Evaluate for anembryonic pregnancy4.75Yes30Evaluate for abnormal yolk sac4.39Yes31Evaluate for increased nuchal translucency4.46Yes32Evaluate for subchorionic hemorrhage4.33Yes33with pregnancy4.60YesEvaluate for increased abortion, and4.60Yes   |    |  |       |     |            |
| 25chorionicity/amnionicity)4.84YesFirst Trimester Abnormalities and Complications26Evaluate for gestational trophoblastic disease4.62Yes27Evaluate for ectopic and heterotopic pregnancy4.92Yes28Evaluate for embryonic/fetal demise4.84Yes29Evaluate for anembryonic pregnancy4.75Yes30Evaluate for abnormal yolk sac4.39Yes31Evaluate for increased nuchal translucency4.46Yes32Evaluate for subchorionic hemorrhage4.33Yes33with pregnancy4.60Yes4Evaluate for increased abortion, and4.60Yes  | 24 |  | 4.32  | Yes |            |
| First Trimester Abnormalities and ComplicationsImage: Complexity of the state of the |    |  |       |     |            |
| 26Evaluate for gestational trophoblastic disease4.62Yes27Evaluate for ectopic and heterotopic pregnancy4.92Yes28Evaluate for embryonic/fetal demise4.84Yes29Evaluate for anembryonic pregnancy4.75Yes30Evaluate for abnormal yolk sac4.39Yes31Evaluate for increased nuchal translucency4.46Yes32Evaluate for subchorionic hemorrhage4.33Yes33with pregnancy4.60YesEvaluate for increased abortion, and4.60Yes  | 25 |  | 4.84  | Yes |            |
| 27Evaluate for ectopic and heterotopic pregnancy4.92Yes28Evaluate for embryonic/fetal demise4.84Yes29Evaluate for anembryonic pregnancy4.75Yes30Evaluate for abnormal yolk sac4.39Yes31Evaluate for increased nuchal translucency4.46Yes32Evaluate for subchorionic hemorrhage4.33Yes33with pregnancy4.60Yes4Evaluate for increased abortion, and4.60Yes  |    | -  |       |     |            |
| 28Evaluate for embryonic/fetal demise4.84Yes29Evaluate for anembryonic pregnancy4.75Yes30Evaluate for abnormal yolk sac4.39Yes31Evaluate for increased nuchal translucency4.46Yes32Evaluate for subchorionic hemorrhage4.33YesEvaluate for intrauterine contraceptive device (IUCD)4.60Yes33with pregnancy4.60Yes   |    |  |       |     |            |
| 29Evaluate for anembryonic pregnancy4.75Yes30Evaluate for abnormal yolk sac4.39Yes31Evaluate for increased nuchal translucency4.46Yes32Evaluate for subchorionic hemorrhage4.33YesEvaluate for intrauterine contraceptive device (IUCD)4.60Yes33with pregnancy4.60YesEvaluate for incomplete/missed abortion, and4.60Yes  |    |  |       |     |            |
| 30Evaluate for abnormal yolk sac4.39Yes31Evaluate for increased nuchal translucency4.46Yes32Evaluate for subchorionic hemorrhage4.33YesEvaluate for intrauterine contraceptive device (IUCD)4.60Yes33with pregnancy4.60YesEvaluate for incomplete/missed abortion, and4.60Yes   | 28 | •  |       |     |            |
| 31Evaluate for increased nuchal translucency4.46Yes32Evaluate for subchorionic hemorrhage4.33YesEvaluate for intrauterine contraceptive device (IUCD)33with pregnancy4.60YesEvaluate for incomplete/missed abortion, and  | 29 |  |       | Yes |            |
| 32Evaluate for subchorionic hemorrhage4.33YesEvaluate for intrauterine contraceptive device (IUCD)4.60Yes33with pregnancy4.60YesEvaluate for incomplete/missed abortion, andImage: Complete/missed abortion, andImage: Complete/missed abortion, and  | 30 | Evaluate for abnormal yolk sac                           | 4.39  | Yes |            |
| Evaluate for intrauterine contraceptive device (IUCD)         33       with pregnancy         Evaluate for incomplete/missed abortion, and  | 31 | Evaluate for increased nuchal translucency               | 4.46  | Yes |            |
| 33     with pregnancy     4.60     Yes       Evaluate for incomplete/missed abortion, and     Image: Complete/missed abortion and text  | 32 | )  | 4.33  | Yes |            |
| Evaluate for incomplete/missed abortion, and  |    |  |       |     |            |
|   | 33 | with pregnancy   | 4.60  | Yes |            |
|   |    | Evaluate for incomplete/missed abortion, and             |       |     |            |
| 54 retained products of conception 4.75 Yes   | 34 | retained products of conception                          | 4.75  | Yes |            |

|      | Assess for first trimester congenital anomalies and  |      |            |   |
|------|--|------|------------|---|
|      | aneuploidy markers (e.g., Trisomy 13, 18, 21, Turner   |      |            |   |
| 35   | syndrome, triploidy)   | 4.50 | Yes        |   |
|      | Obstetrics Second/Third Trimester  |      |            |   |
|      | Normal Anatomy and Physiology - Second/Third<br>Trimester  |      |            |   |
| 36   | Assess the placenta (i.e., size, location)   | 4.75 | Yes        |   |
| 37   | Assess the umbilical cord (e.g., placental insertion, vessel number, fetal insertion)  | 4.73 | Yes        |   |
| 38   | Assess amniotic fluid volume   | 4.70 | Yes        |   |
| 39   | Assess fetal lie, presentation, and situs  | 4.58 | Yes        |   |
| 40   | Assess the fetal heart (i.e., size, position, axis,<br>chambers, valves, four-chamber view, left ventricular<br>outflow tract [LVOT], right ventricular outflow tract<br>[RVOT], aortic arch, ductal arch, three vessel view<br>[3VV] and three-vessel trachea [3VT] view) | 4.76 | Voc        |   |
| 40   | Assess the neck  | 4.76 | Yes<br>Yes |   |
| 41   | Assess the cranial anatomy (e.g., choroid plexus,  | 4.34 | res        |   |
| 42   | lateral cerebral ventricles, midline falx, corpus<br>callosum, cisterna magna, posterior fossa, cavum<br>septi pellucidi, cerebellum, posterior fossa, and<br>nuchal fold)   | 4.79 | Yes        |   |
|      | Assess the face (e.g., nose, lips, chin, palate, nasal   |      |            |   |
| 43   | bone, orbits, frontal bone, profile view)  | 4.71 | Yes        |   |
| 44   | Assess the diaphragm   | 4.66 | Yes        |   |
| 45   | Assess the thorax (i.e., thymus, lungs)  | 4.29 | Yes        |   |
| 46   | Assess the abdomen and gastrointestinal system<br>(i.e., gallbladder, stomach, bowel, adrenal glands,<br>liver, spleen)  | 4.53 | Yes        |   |
| 47   | Assess the skeletal system (e.g., skull, cranial contour, long bones, ribs, ossification)  | 4.61 | Yes        |   |
| 48   | Assess the vertebral spine (e.g., ossification centers, curvature, skin covering)  | 4.71 | Yes        |   |
| 49   | Assess the upper and lower extremities (i.e., number, position, digits and spacing)  | 4.50 | Yes        |   |
| - F0 | Access the genitalia   | 2.00 | Voc        | Committee<br>thought this<br>was important<br>to ID |
| 50   | Assess the genitalia<br>Assess the genitourinary system (e.g., kidneys,  | 3.90 | Yes        | pathologies   |
| 51   | bladder)   | 4.72 | Yes        |   |
|      | Fetal Abnormalities - Second/Third Trimester   |      |            | "Congenital<br>anomalies"                           |

|    |   |      |     | changed to<br>abnormalities   |
|----|---|------|-----|---|
| 50 | Assess abnormal multiple gestations (e.g., discordant<br>growth >20%, twin to twin transfusion syndrome,<br>selective intrauterine growth restriction [SIUGR],<br>twin reversed arterial perfusion sequence [TRAP],<br>twin anemia polycythemia sequence [TAPS],                                      | 4.70 | N   |   |
| 52 | conjoined twins)<br>Evaluate for 2nd and 3rd trimester congenital   | 4.78 | Yes | "Assess"  |
| 53 | anomalies and aneuploidy markers (e.g., Trisomy 13, 18, 21, Turner syndrome, triploidy)   | 4.72 | Yes | changed to<br>"Evaluate"  |
| 54 | Evaluate for abnormal amniotic fluid volume   | 4.75 | Yes |   |
|    | Evaluate for abnormal fetal growth (e.g.,<br>macrosomia, fetal growth restriction [FGR], small for  |      |     | "intrauterine<br>growth<br>restriction<br>(IUGR)"<br>changed to<br>"fetal growth<br>restriction<br>(FGR)" |
| 55 | gestation age [SGA])  | 4.79 | Yes | example   |
| 56 | Evaluate for abnormal central nervous system (e.g.,<br>ventriculomegaly, anencephaly, acrania,<br>hydranencephaly, holoprosencephaly, Dandy-Walker<br>malformation, Chiari II malformation, agenesis of<br>corpus callosum, encephalocele, meningocele,<br>myelomeningocele, sacrococcygeal teratoma) | 4.80 | Yes |   |
| 57 | Evaluate for abnormal face (cleft lip/palate, hyper-<br>/hypo-telorism, micrognathia, frontal bossing)  | 4.68 | Yes |   |
| 58 | Evaluate for abnormal neck (e.g., goiter, cystic hygroma)   | 4.59 | Yes |   |
| 59 | Evaluate for abnormal fetal heart (e.g., atrial and<br>ventricular septal defects, atrioventricular canal<br>defect, tetralogy of Fallot, transposition of the great<br>vessels, pentalogy of Cantrell, pericardial effusion,<br>rhabdomyoma)   | 4.77 | Yes |   |
| 60 | Evaluate for abnormal diaphragm (e.g., congenital diaphragmatic hernia, eventration)  | 4.69 | Yes |   |
|    | Evaluate for abnormal thorax (e.g., hydrops, pleural<br>effusion, congenital pulmonary adenomatoid<br>malformation, pulmonary sequestration,  |      |     |   |
| 61 | bronchogenic cyst)  | 4.65 | Yes |   |
| 62 | Evaluate for abdominal wall defect (e.g., omphalocele, gastroschisis)   | 4.75 | Yes |   |

|    | Evaluate for abnormal abdomen and gastrointestinal      |      | 1   |                   |
|----|---|------|-----|-------------------|
|    | system (i.e., ascites, hydrops, neuroblastoma,          |      |     | "Assess"          |
|    | echogenic bowel, bowel obstruction, esophageal and      |      |     | changed to        |
| 63 | duodenal atresia, mesenteric cyst)                      | 4.71 | Yes | "Evaluate"        |
|    | Evaluate for abnormal genitourinary system (e.g.,       |      |     |                   |
|    | hydronephrosis, cystic renal dysplasia, hydroureter,    |      |     |                   |
|    | renal agenesis, bladder outlet obstruction,             |      |     |                   |
| 64 | ureterocele, ambiguous genitalia, ovarian cyst)         | 4.73 | Yes |                   |
|    | Evaluate for abnormal skeletal system (e.g., vertebral  |      |     |                   |
|    | spine, skeletal dysplasia, demineralization, limb       |      |     |                   |
| 65 | reduction, agenesis)                                    | 4.73 | Yes |                   |
|    | Evaluate for abnormal extremities including hands       |      |     |                   |
|    | and feet (e.g., polydactyly, talipes, syndactyly,       |      |     |                   |
| 66 | clinodactyly)   | 4.47 | Yes |                   |
|    | Placental and umbilical cord abnormalities              |      |     |                   |
|    | Evaluate for placenta previa (i.e., complete, low-      |      |     | Removed           |
| 67 | lying)  | 4.87 | Yes | "partial" as i.e. |
|    |   |      |     | added comma       |
|    |   |      |     | between           |
|    | Evaluate for placenta abruption and infarction (i.e.,   |      |     | retroplacental    |
| 68 | retroplacental, marginal)                               | 4.84 | Yes | and marginal      |
|    | Evaluate for abnormal placental attachment (i.e.,       |      |     | changed "e.g."    |
| 69 | placenta accreta, increta, percreta)                    | 4.79 | Yes | to "i.e."         |
|    | Evaluate for abnormal placental membrane                |      |     |                   |
|    | attachment, insertion, or shape (e.g., circumvallate,   |      |     |                   |
|    | succenturiate, velamentous, accessory lobe, vasa        |      |     |                   |
| 70 | previa)   | 4.69 | Yes |                   |
|    | Evaluate for other placental and membrane               |      |     |                   |
|    | abnormalities (e.g., thickened placenta,                |      |     | "Assess"          |
|    | chorioangioma, amniotic bands, synechia, premature      |      |     | changed to        |
| 71 | rupture of membranes)                                   | 4.65 | Yes | "Evaluate"        |
|    | Evaluate for abnormal umbilical cord (e.g., single      |      |     |                   |
| 72 | umbilical artery, nuchal cord, allantoic cysts, length) | 4.64 | Yes |                   |
|    | Cervix and maternal pathology                           |      |     |                   |
|    |   |      |     | "Assess"          |
|    | Evaluate for cervical incompetence (e.g., shortening,   |      |     | changed to        |
| 73 | funneling, and cerclage)                                | 4.79 | Yes | "Evaluate"        |
|    |   |      |     | "Assess"          |
|    | Evaluate for maternal pelvic pathology (e.g., ovarian   |      |     | changed to        |
| 74 | cysts, cystic teratoma, pelvic kidney)                  | 4.21 | Yes | "Evaluate"        |

|    | Protocols and Procedures   |      |     | Added<br>"Procedures"<br>to domain title<br>because<br>moved original<br>"Treatment"<br>Domain to a<br>subdomain<br>under this.<br>Task<br>weightings<br>were added to<br>this domain |
|----|--|------|-----|---|
|    | Clinical standards and guidelines  |      |     |   |
|    | Verify accuracy of physician order and obtain<br>pertinent clinical history from the patient and/or                  |      |     |   |
| 75 | medical records  | 4.74 | Yes |   |
|    | Correlate ultrasound findings with clinical  | , 1  | 105 |   |
|    | presentation, previous imaging, and lab results (e.g.,   |      |     |   |
| 76 | hCG levels, genetic testing, CA 125)   | 4.64 | Yes |   |
| 77 | Utilize appropriate scanning technique and patient preparation (i.e., transabdominal, transvaginal, and translabial) | 4.77 | Yes | Added "i.e."  |
|    | Recognize ultrasound findings that require   | 4.77 | 165 | Audeu I.e.  |
|    | immediate action (e.g., ovarian torsion, fetal demise,   |      |     |   |
| 78 | ectopic pregnancy)   | 4.94 | Yes |   |
|    | Measurement Techniques - Gynecology  |      |     |   |
| 79 | Measure endometrium thickness  | 4.63 | Yes |   |
| 80 | Measure uterus and ovaries   | 4.52 | Yes |   |
|    | Measurement Techniques - Obstetric   |      |     |   |
|    | Measure first trimester structures (i.e., crown rump   |      |     |   |
| 81 | length, mean sac diameter, yolk sac)   | 4.84 | Yes |   |
| 82 | Measure nuchal translucency  | 4.26 | Yes |   |
|    |  |      |     | Covered by  |
|    |  |      |     | Tasks 35 and  |
| 83 | Measure the nasal bone   | 3.73 | No  | 43  |
| 84 | Measure biparietal diameter  | 4.70 | Yes |   |
| 85 | Measure head circumference   | 4.75 | Yes |   |
| 86 | Measure cisterna magnum  | 4.42 | Yes |   |
| 87 | Measure transverse cerebellar diameter   | 4.36 | Yes |   |
| 88 | Measure lateral cerebral ventricle   | 4.45 | Yes |   |
| 89 | Obtain cephalic index<br>Measure nuchal fold between 15 and 20 weeks'  | 4.09 | Yes |   |
| 90 | gestation  | 4.06 | Yes |   |

|     |   |      |     | Covered by             |
|-----|---|------|-----|------------------------|
|     |   |      |     | Tasks 35 and           |
| 91  | Measure orbits, inner and outer orbital diameters     | 3.57 | No  | 43                     |
| 92  | Measure abdominal circumference                       | 4.77 | Yes |                        |
|     | Measure long bones (i.e., femur, humerus, fibula,     |      |     |                        |
| 93  | radius, ulna, tibia)                                  | 4.56 | Yes |                        |
|     |   |      |     | Committee              |
| 0.4 |   | 4.00 | Vee | thought this is        |
| 94  | Measure renal pelves                                  | 4.00 | Yes | important              |
|     | Measure amniotic fluid (i.e., amniotic fluid index,   |      |     |                        |
| 95  | maximum vertical pocket)                              | 4.65 | Yes |                        |
| 96  | Perform biophysical profile                           | 4.38 | Yes |                        |
| 97  | Measure maternal cervix                               | 4.58 | Yes |                        |
|     | Physics and Instrumentation                           |      |     |                        |
|     | Hemodynamics - Gynecology                             |      |     |                        |
|     |   |      |     | Covered by             |
| 98  | Assess uterine vasculature with Doppler               | 3.54 | No  | Task 99                |
|     | Assess pelvic vasculature with Doppler (e.g., ovarian |      |     | Added                  |
| 99  | perfusion, uterine varices)                           | 4.25 | Yes | examples               |
| 100 | Assess arteriovenous malformations using Doppler      | 4.03 | Yes |                        |
|     | Hemodynamics - Obstetric                              |      |     |                        |
|     | Assess embryonic and/or fetal heart rate and rhythm   |      |     |                        |
| 101 | with M-mode or cine clip                              | 4.83 | Yes |                        |
|     |   |      |     | Important to           |
|     |   |      |     | include;               |
|     |   |      |     | changed                |
|     |   |      |     | "assess" to            |
| 102 | Identify the middle cerebral artery with Doppler      | 3.68 | Yes | "identify"             |
|     |   |      |     | Important to           |
|     |   |      |     | include;               |
|     |   |      |     | changed<br>"assess" to |
| 103 | Identify the ductus venosus with Doppler              | 3.63 | Yes | "identify"             |
| 103 | Assess the umbilical cord vessels with Doppler        | 4.14 | Yes | lucitity               |
| 104 | · · ·   | 4.14 | 165 |                        |
|     | Imaging Instruments                                   |      |     | Changed                |
|     |   |      |     | "apply" to             |
| 105 | Utilize M-mode  | 4.72 | Yes | "utilize"              |
|     |   |      |     | Changed                |
|     |   |      |     | "apply" to             |
| 106 | Utilize Doppler (i.e., color, power, pulsed-wave)     | 4.20 | Yes | "utilize"              |
|     |   |      |     | Important to           |
|     |   |      |     | include;               |
| 107 | Utilize 3-D imaging                                   | 3.00 | Yes | changed                |

|     |  |      |     | "perform" to<br>"utilize" |
|-----|--|------|-----|---------------------------|
|     | Apply ALARA principle (e.g., thermal index,        |      |     |                           |
| 108 | mechanical index)                                  | 4.68 | Yes |                           |
|     |  |      |     | Moved to be a             |
|     |  |      |     | subdomain in              |
|     |  |      |     | "Protocols and            |
|     |  |      |     | Procedures"               |
|     | Treatment  |      |     | Domain                    |
|     | Sonographer Role in Procedures                     |      |     |                           |
|     |  |      |     | Changed                   |
|     | Provide ultrasound assistance and documentation    |      |     | "guidance" to             |
| 109 | for sonohysterography                              | 4.23 | Yes | "assistance"              |
|     |  |      |     | Changed                   |
|     | Provide ultrasound assistance for amniocentesis    |      |     | "guidance" to             |
| 110 | after 15 weeks' gestation                          | 4.26 | Yes | "assistance"              |
|     |  |      |     | Changed                   |
|     | Provide ultrasound assistance for chorionic villus |      |     | "guidance" to             |
| 111 | sampling   | 4.19 | Yes | "assistance"              |
|     |  |      |     | Important to              |
|     |  |      |     | include;                  |
|     |  |      |     | Changed                   |
|     | Provide ultrasound assistance for intrauterine     |      |     | "guidance" to             |
| 112 | contraceptive device placement procedure           | 3.73 | Yes | "assistance"              |
|     |  |      |     | Changed                   |
|     | Provide ultrasound assistance and documentation    |      |     | "guidance" to             |
| 113 | for infertility examinations and procedures        | 4.14 | Yes | "assistance"              |

# Appendix E: Demographics of Survey Respondents





Figure 1. Gender Identification of Population Compared to Survey Respondents

Figure 2. Age of Population Compared to Survey Respondents






Figure 3. Comparison of Country of Residence for Population and of Survey Respondents

Figure 4. Comparison of U.S. Census Region of Population and Survey Respondents




Figure 5. Primary Job Function of Population





Figure 6. Primary Job Function of Survey Respondents








Figure 7. Survey Respondents Years of Performing OB/GYN Ultrasound Examination









## Appendix G: Content Outline



### Obstetrics and Gynecology Examination Content Outline (Outline Summary)

| # | Domain  | Subdomain   | Percentage |
|---|---|---|------------|
| 1 | Gynecology - Pelvic Anatomy<br>and Physiology | <ul><li>Normal Anatomy and Physiology</li><li>Abnormal Physiology and Perfusion</li></ul>   | 19%        |
| 2 | <b>Obstetrics - First Trimester</b>           | <ul><li>Normal Anatomy and Physiology First Trimester</li><li>First Trimester Abnormalities and Complications</li></ul>   | 12%        |
| 3 | Obstetrics Second/Third<br>Trimester          | <ul> <li>Normal Anatomy and Physiology - Second/Third<br/>Trimester</li> <li>Fetal Abnormalities - Second/Third Trimester</li> <li>Placental and Umbilical Cord Abnormalities</li> <li>Cervix and Maternal Pathology</li> </ul> | 37%        |
| 4 | Protocols and Procedures                      | <ul> <li>Clinical Standards and Guidelines</li> <li>Measurement Techniques - Gynecology</li> <li>Measurement Techniques - Obstetric</li> <li>Sonographer Role in Procedures</li> </ul>  | 24%        |
| 5 | Physics and Instrumentation                   | <ul><li>Hemodynamics - Gynecology</li><li>Hemodynamics - Obstetric</li><li>Imaging Instruments</li></ul>  | 8%         |

### (Detailed Outline)

| 1.     | Gynecology - Pelvic Anatomy and Physiology 19%                               |
|--------|--|
| 1.A.   | Normal Anatomy and Physiology  |
| 1.A.1. | Assess the uterus (i.e., size, position, orientation, contour, echogenicity) |
| 1.A.2. | Assess the myometrium  |
| 1.A.3. | Assess the endometrium (i.e., cyclic changes)                                |
| 1.A.4. | Assess the vagina and cervix   |
| 1.A.5. | Assess both adnexa (i.e., ovaries, fallopian tubes, pelvic musculature)      |
| 1.A.6. | Assess the anterior and posterior cul-de-sacs                                |
| 1.A.7. | Assess premenarcheal, reproductive, and postmenopausal patients              |

| 1.B.    | Abnormal Physiology and Perfusion  |
|---------|--|
| 1.B.1.  | Evaluate for Müllerian duct developmental anomalies (e.g., septated, subseptate, arcuate, bicornuate, unicornis uterus)  |
| 1.B.2.  | Evaluate for abnormal fluid collections (e.g., hydrometra, pyometra, hydrometrocolpos, hematometrocolpos, free fluid)  |
| 1.B.3.  | Evaluate for uterine leiomyomas (e.g., intramural, submucosal, subserosal, pedunculated)   |
| 1.B.4.  | Evaluate for adenomyosis and endometriosis (e.g., endometrioma)  |
| 1.B.5.  | Evaluate for endometrial pathology (e.g., endometrial fluid, polyps, endometrial hyperplasia, endometrial carcinoma)   |
| 1.B.6.  | Evaluate for cervical pathology (e.g., polyps, nabothian cysts, cervical stenosis, cervical carcinoma)   |
| 1.B.7.  | Evaluate other uterine findings (e.g., caesarean-section scar, leiomyosarcoma)   |
| 1.B.8.  | Evaluate for functional ovarian cysts (e.g., follicular, corpus luteum, theca-lutein)  |
| 1.B.9.  | Evaluate for benign ovarian neoplasms (e.g., paraovarian, cystadenoma [serous, mucinous, papillary], cystic teratoma, fibroma, thecoma, arrhenoblastoma)               |
| 1.B.10. | Evaluate for malignant ovarian neoplasms (e.g., serous carcinoma, mucinous cystadenocarcinoma, papillary cystadenocarcinoma, metastatic, Krukenberg)                   |
| 1.B.11. | Evaluate other ovarian findings (e.g., ovarian torsion, ovarian hyperstimulation syndrome, polycystic ovarian disease)   |
| 1.B.12. | Assess for pelvic inflammatory disease (e.g., endometritis, pyosalpinx, tubo-ovarian abscess)  |
| 1.B.13. | Assess for intrauterine contraceptive device (IUCD) location   |
| 2.      | Obstetrics - First Trimester 12%   |
| 2.A.    | Normal Anatomy and Physiology First Trimester  |
| 2.A.1.  | Identify structures in the first-trimester obstetric examination at less than 10 weeks' gestation (i.e., decidual reaction, gestational sac, yolk sac, embryo, amnion) |
| 2.A.2.  | Identify fetal anatomy in the first trimester obstetrical examination between 10-14 weeks' gestation (i.e., calvarium, brain, stomach, cord insertion, limbs)          |
| 2.A.3.  | Identify multiple gestations (i.e., fetal number, chorionicity/amnionicity)  |
| 2.B.    | First Trimester Abnormalities and Complications  |
| 2.B.1.  | Evaluate for gestational trophoblastic disease   |
| 2.B.2.  | Evaluate for ectopic and heterotopic pregnancy   |
| 2.B.3.  | Evaluate for embryonic/fetal demise  |
| 2.B.4.  | Evaluate for anembryonic pregnancy   |
| 2.B.5.  | Evaluate for abnormal yolk sac   |
| 2.B.6.  | Evaluate for increased nuchal translucency   |
| 2.B.7.  | Evaluate for subchorionic hemorrhage   |
| 2.B.8.  | Evaluate for intrauterine contraceptive device (IUCD) with pregnancy   |
| 2.B.9.  | Evaluate for incomplete/missed abortion, and retained products of conception   |
| 2.B.10. | Assess for first trimester congenital anomalies and aneuploidy markers (e.g., Trisomy 13, 18, 21, Turner syndrome, triploidy)  |

| 3.      | Obstetrics Second/Third Trimester 37%   |
|---------|---|
| 3.A.    | Normal Anatomy and Physiology - Second/Third Trimester  |
| 3.A.1.  | Assess the placenta (i.e., size, location)  |
| 3.A.2.  | Assess the umbilical cord (e.g., placental insertion, vessel number, fetal insertion)   |
| 3.A.3.  | Assess amniotic fluid volume  |
| 3.A.4.  | Assess fetal lie, presentation, and situs   |
| 3.A.5.  | Assess the cranial anatomy (e.g., choroid plexus, lateral cerebral ventricles, midline falx, corpus callosum, cisterna magna, posterior fossa, cavum septi pellucidi, cerebellum, posterior fossa, and nuchal fold)   |
| 3.A.6.  | Assess the neck   |
| 3.A.7.  | Assess the face (e.g., nose, lips, chin, palate, nasal bone, orbits, frontal bone, profile view)  |
| 3.A.8.  | Assess the fetal heart (i.e., size, position, axis, chambers, valves, four-chamber view, left ventricular outflow tract [LVOT], right ventricular outflow tract [RVOT], aortic arch, ductal arch, three vessel view [3VV] and three-vessel trachea [3VT] view)                                  |
| 3.A.9.  | Assess the thorax (i.e., thymus, lungs)   |
| 3.A.10. | Assess the diaphragm  |
| 3.A.11. | Assess the abdomen and gastrointestinal system (i.e., gallbladder, stomach, bowel, adrenal glands, liver, spleen)   |
| 3.A.12. | Assess the genitourinary system (e.g., kidneys, bladder)  |
| 3.A.13. | Assess the skeletal system (e.g., skull, cranial contour, long bones, ribs, ossification)   |
| 3.A.14. | Assess the vertebral spine (e.g., ossification centers, curvature, skin covering)   |
| 3.A.15. | Assess the upper and lower extremities (i.e., number, position, digits and spacing)   |
| 3.A.16. | Assess the genitalia  |
| 3.B.    | Fetal Abnormalities - Second/Third Trimester  |
| 3.B.1.  | Assess abnormal multiple gestations (e.g., discordant growth >20%, twin to twin transfusion syndrome, selective intrauterine growth restriction [SIUGR], twin reversed arterial perfusion sequence [TRAP], twin anemia polycythemia sequence [TAPS], conjoined twins)                           |
| 3.B.2.  | Evaluate for 2nd and 3rd trimester congenital anomalies and aneuploidy markers (e.g., Trisomy 13, 18, 21, Turner syndrome, triploidy)   |
| 3.B.3.  | Evaluate for abnormal amniotic fluid volume   |
| 3.B.4.  | Evaluate for abnormal fetal growth (e.g., macrosomia, fetal growth restriction [FGR], small for gestation age [SGA])  |
| 3.B.5.  | Evaluate for abnormal central nervous system (e.g., ventriculomegaly, anencephaly, acrania,<br>hydranencephaly, holoprosencephaly, Dandy-Walker malformation, Chiari II malformation,<br>agenesis of corpus callosum, encephalocele, meningocele, myelomeningocele, sacrococcygeal<br>teratoma) |
| 3.B.6.  | Evaluate for abnormal neck (e.g., goiter, cystic hygroma)   |
| 3.B.7.  | Evaluate for abnormal face (cleft lip/palate, hyper-/hypotelorism, micrognathia, frontal bossing)   |
| 3.B.8.  | Evaluate for abnormal fetal heart (e.g., atrial and ventricular septal defects, atrioventricular canal defect, tetralogy of Fallot, transposition of the great vessels, pentalogy of Cantrell, pericardial  |

|             | effusion, rhabdomyoma)   |
|-------------|--|
| 3.B.9.      | Evaluate for abnormal diaphragm (e.g., congenital diaphragmatic hernia, eventration)   |
| 3.B.10.     | Evaluate for abnormal thorax (e.g., hydrops, pleural effusion, congenital pulmonary adenomatoid malformation, pulmonary sequestration, bronchogenic cyst)  |
| 3.B.11.     | Evaluate for abdominal wall defect (e.g., omphalocele, gastroschisis)  |
| 3.B.12.     | Evaluate for abnormal abdomen and gastrointestinal system (i.e., ascites, hydrops, neuroblastoma, echogenic bowel, bowel obstruction, esophageal and duodenal atresia, mesenteric cyst)                  |
| 3.B.13.     | Evaluate for abnormal genitourinary system (e.g., hydronephrosis, cystic renal dysplasia,<br>hydroureter, renal agenesis, bladder outlet obstruction, ureterocele, ambiguous genitalia,<br>ovarian cyst) |
| 3.B.14.     | Evaluate for abnormal skeletal system (e.g., vertebral spine, skeletal dysplasia, demineralization, limb reduction, agenesis)  |
| 3.B.15.     | Evaluate for abnormal extremities including hands and feet (e.g. polydactyly, talipes, syndactyly, clinodactyly)   |
| 3.C.        | Placental and Umbilical Cord Abnormalities   |
| 3.C.1.      | Evaluate for placenta previa (i.e., complete, low-lying)   |
| 3.C.2.      | Evaluate for placenta abruption and infarction (i.e., retroplacental, marginal)  |
| 3.C.3.      | Evaluate for abnormal placental attachment (i.e., placenta accreta, increta, percreta)   |
| 3.C.4.      | Evaluate for abnormal placental membrane attachment, insertion, or shape (e.g., circumvallate, succenturiate, velamentous, accessory lobe, vasa previa)  |
| 3.C.5.      | Evaluate for other placental and membrane abnormalities (e.g., thickened placenta, chorioangioma, amniotic bands, synechia, premature rupture of membranes)  |
| 3.C.6.      | Evaluate for abnormal umbilical cord (e.g., single umbilical artery, nuchal cord, allantoic cysts, length)   |
| 3.D.        | Cervix and Maternal Pathology  |
| 3.D.1.      | Evaluate for cervical incompetence (e.g., shortening, funneling, and cerclage)   |
| 3.D.2.      | Evaluate for maternal pelvic pathology (e.g., ovarian cysts, cystic teratoma, pelvic kidney)   |
| 4.          | Protocols and Procedures 24%   |
| <b>4.A.</b> | Clinical Standards and Guidelines  |
| 4.A.1.      | Verify accuracy of physician order and obtain pertinent clinical history from the patient and/or medical records   |
| 4.A.2.      | Correlate ultrasound findings with clinical presentation, previous imaging, and lab results (e.g., hCG levels, genetic testing, CA 125)  |
| 4.A.3.      | Utilize appropriate scanning technique and patient preparation (i.e., transabdominal, transvaginal, and translabial)   |
| 4.A.4.      | Recognize ultrasound findings that require immediate action (e.g., ovarian torsion, fetal demise, ectopic pregnancy)   |
| 4.B.        | Measurement Techniques - Gynecology  |
| 4.B.1.      | Measure endometrium thickness  |
| 4.B.2.      | Measure uterus and ovaries   |
| 4.C.        | Measurement Techniques - Obstetric   |

| 4.C.1.  | Measure first trimester structures (i.e., crown rump length, mean sac diameter, yolk sac)   |
|---|---|
| 4.C.2.  | Measure nuchal translucency   |
| 4.C.3.  | Measure biparietal diameter   |
| 4.C.4.  | Measure head circumference  |
| 4.C.5.  | Measure cisterna magnum   |
| 4.C.6.  | Measure transverse cerebellar diameter  |
| 4.C.7.  | Measure lateral cerebral ventricle  |
| 4.C.8.  | Obtain cephalic index   |
| 4.C.9.  | Measure nuchal fold between 15 and 20 weeks' gestation  |
| 4.C.10.   | Measure abdominal circumference   |
| 4.C.11.   | Measure long bones (i.e., femur, humerus, fibula, radius, ulna, tibia)  |
| 4.C.12.   | Measure renal pelves  |
| 4.C.13.   | Measure amniotic fluid (i.e., amniotic fluid index, maximum vertical pocket)  |
| 4.C.14.   | Perform biophysical profile   |
| 4.C.15.   | Measure maternal cervix   |
| 4.D.  | Sonographer Role in Procedures  |
| 4.D.1.  | Provide ultrasound assistance and documentation for sonohysterography   |
| 4.D.2.  | Provide ultrasound assistance for amniocentesis after 15 weeks' gestation   |
| 4.D.3.  | Provide ultrasound assistance for chorionic villus sampling   |
| 4.D.4.  | Provide ultrasound assistance for intrauterine contraceptive device placement   |
| 4.D.5.  | Provide ultrasound assistance and documentation for infertility examinations and procedures   |
| 5.  |   |
|   | Physics and Instrumentation 8%  |
| 5.A.  | Physics and Instrumentation 8%         Hemodynamics - Gynecology  |
|   |   |
| 5.A.  | Hemodynamics - Gynecology   |
| <b>5.A.</b><br>5.A.1.   | Hemodynamics - Gynecology         Assess pelvic vasculature with Doppler (e.g., ovarian perfusion, uterine varices)   |
| <b>5.A.</b><br>5.A.1.<br>5.A.2.   | Hemodynamics - Gynecology         Assess pelvic vasculature with Doppler (e.g., ovarian perfusion, uterine varices)         Assess arteriovenous malformations using Doppler  |
| <b>5.A.</b><br>5.A.1.<br>5.A.2.<br><b>5.B.</b>  | Hemodynamics - Gynecology         Assess pelvic vasculature with Doppler (e.g., ovarian perfusion, uterine varices)         Assess arteriovenous malformations using Doppler         Hemodynamics - Obstetric   |
| <b>5.A.</b><br>5.A.1.<br>5.A.2.<br><b>5.B.</b><br>5.B.1.  | Hemodynamics - Gynecology         Assess pelvic vasculature with Doppler (e.g., ovarian perfusion, uterine varices)         Assess arteriovenous malformations using Doppler         Hemodynamics - Obstetric         Assess embryonic and/or fetal heart rate and rhythm with M-mode or cine clip  |
| <b>5.A.</b><br>5.A.1.<br>5.A.2.<br><b>5.B.</b><br>5.B.1.<br>5.B.2.  | Hemodynamics - Gynecology         Assess pelvic vasculature with Doppler (e.g., ovarian perfusion, uterine varices)         Assess arteriovenous malformations using Doppler         Hemodynamics - Obstetric         Assess embryonic and/or fetal heart rate and rhythm with M-mode or cine clip         Identify the middle cerebral artery with Doppler   |
| <b>5.A.</b><br>5.A.1.<br>5.A.2.<br><b>5.B.</b><br>5.B.1.<br>5.B.2.<br>5.B.3.                                    | Hemodynamics - GynecologyAssess pelvic vasculature with Doppler (e.g., ovarian perfusion, uterine varices)Assess arteriovenous malformations using DopplerHemodynamics - ObstetricAssess embryonic and/or fetal heart rate and rhythm with M-mode or cine clipIdentify the middle cerebral artery with DopplerIdentify the ductus venosus with Doppler  |
| <b>5.A.</b><br>5.A.1.<br>5.A.2.<br><b>5.B.</b><br>5.B.1.<br>5.B.2.<br>5.B.3.<br>5.B.4.                          | Hemodynamics - GynecologyAssess pelvic vasculature with Doppler (e.g., ovarian perfusion, uterine varices)Assess arteriovenous malformations using DopplerHemodynamics - ObstetricAssess embryonic and/or fetal heart rate and rhythm with M-mode or cine clipIdentify the middle cerebral artery with DopplerIdentify the ductus venosus with DopplerAssess the umbilical cord vessels with Doppler                                  |
| <b>5.A.</b><br>5.A.1.<br>5.A.2.<br><b>5.B.</b><br>5.B.1.<br>5.B.2.<br>5.B.3.<br>5.B.4.<br><b>5.C.</b>           | Hemodynamics - GynecologyAssess pelvic vasculature with Doppler (e.g., ovarian perfusion, uterine varices)Assess arteriovenous malformations using DopplerHemodynamics - ObstetricAssess embryonic and/or fetal heart rate and rhythm with M-mode or cine clipIdentify the middle cerebral artery with DopplerIdentify the ductus venosus with DopplerAssess the umbilical cord vessels with DopplerImaging Instruments               |
| <b>5.A.</b><br>5.A.1.<br>5.A.2.<br><b>5.B.</b><br>5.B.1.<br>5.B.2.<br>5.B.3.<br>5.B.4.<br><b>5.C.</b><br>5.C.1. | Hemodynamics - GynecologyAssess pelvic vasculature with Doppler (e.g., ovarian perfusion, uterine varices)Assess arteriovenous malformations using DopplerHemodynamics - ObstetricAssess embryonic and/or fetal heart rate and rhythm with M-mode or cine clipIdentify the middle cerebral artery with DopplerIdentify the ductus venosus with DopplerAssess the umbilical cord vessels with DopplerImaging InstrumentsUtilize M-mode |